口服美沙拉嗪联合康复新液灌肠治疗溃疡性结肠炎的疗效及其对凝血指标的影响

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (728 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of oral administration of mesalazine in combination with Kangfuxin solution enema in the treatment of ulcerative colitis (UC) and its effects on coagulation parameters. Methods 80 patients with UC meeting the inclusion criteria were randomly divided into observation group (n=40) and the control group(n=40) according to the treatment plan in digital form. The control group was treated with oral administration of mesalazine, while the observation group was treated in combination with Kangfuxin solution enema on the basis of the control group. After the treatment, the two groups of patients were compared in clinical efficacy and coagulation parameters index changes. And they were followed up for 6 months, the recurrence rate was observed and compared. Results The observation group had a total effective rate of 95.0%, which was higher than that of 75.0% in the control group (P＜0.05). In coagulation parameters indexes : the count of platelets (PLT)(189.1±94.5)and concentration of fibrinogen (FIB)(2.4±0.2)were lower in the observation group after treatment, while the prothrombin time (PT)(13.9±1.6) and mean platelet volume (MPV)(9.8±0.5)were higher (P<0.05), and the corresponding indexes(212.6±97.2;3.3±0.3;10.8±1.2;7.4±0.6)compared with those in the control group showed statistical significance (P<0.05). After six-month follow-up, it was shown that the observation group had a lower recurrence rate of 7.5% than that of 27.5% in the control group (P＜0.05). Conclusions Oral administration of mesalazine in combination with Kangfuxin solution enema in the treatment of UC can obviously relieve the clinical symptoms, improve the effect of treatment and coagulation parameters indexes, reduce the recurrence rate;it is worth of further clinical research.

Key words： Mesalazine Kangfuxin solution enema ulcerative colitis coagulation parameters

Received: 11 December 2014

ZTFLH:

R574.621

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GONG Junqing
	YAN Chunfeng
	ZHANG Lisheng

Cite this article:

GONG Junqing,YAN Chunfeng,ZHANG Lisheng. Curative efficacy of mesalazine in combination with Kangfuxin solution enema in treatment of ulcerative colitis and its effects on coagulation parameters[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2015, 26(5): 440-443.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2015/V26/I5/440

[1]	Panaccinone R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis[J]. Gastroenterology,2014, 146(2):392-400.
[2]	Han J, Wang J, Wang J H. Effects of jianpi herbal suppository on hemorheology and CD62P in patients with ulcerative colitis[J]. J Tradit Chin Med,2014,34(2):155-158.
[3]	张岩,姜挺,夏冰,等.溃疡性结肠炎患者药物保留灌肠效果的Meta分析[J].护理学杂志,2009,24(23):69-72.
[4]	陈曦,田耀州,夏军权,等.溃疡性结肠炎治疗研究进展[J].南京中医药大学学报,2013,29(3):293-296.
[5]	薛林云,欧阳钦.世界胃肠病组织推荐的IBD全球实践指南[J].国际消化病杂志,2010,30(4) :195-199.
[6]	中华消化病学分会炎性反应性肠病协作组.对我国炎性反应性肠病诊断治疗规范的共识意见[J].现代消化及介入治疗,2008,13(2):139-145.
[7]	潘庚,朱桢.改良康复新液保留灌肠治疗溃疡性结肠炎疗效及对血清凝血指标的影响[J].河北医药,2012,34(11):1623-1625.
[8]	David B S. Management of acute, severe ulcerative colitis[J]. J Dig Dis,2012,13(2):65-68.
[9]	黄瑞珍,马慧萍,张宝莲,等.药物灌肠治疗溃疡性结肠炎的观察及护理[J].中国中医急症,2009,18(9):1562-1563.
[10]	陈志辉,刘阳优,陈彩秀,等.美沙拉嗪颗粒和柳氮磺胺吡啶治疗溃疡性结肠炎的随机对照研究[J].临床和实验医学杂志,2009,8(7):73-74.
[11]	郑利,韦东,李秋勇,等.康复新液保留灌肠治疗溃疡性结肠炎的临床观察[J].中国社区医师,2013,15(5):87.
[12]	黄夺夏,陆翠钦,何张平.美沙拉嗪与康复新液联合治疗老年溃疡性结肠炎的疗效及对血清炎性反应细胞因子、凝血指标的影响[J].中国老年学杂志,2013,33(8):3769-3770.
[13]	潘文.康复新液灌肠治疗溃疡性结肠炎40例[J].陕西中医,2012,33(9):1125-1127.
[14]	范光学,孙玉娟,毛春梅,等.康复新液灌肠联合柳氮磺吡啶治疗溃疡性结肠炎临床观察[J].现代中西医结合杂志,2014,23(13):1436-1438.
[15]	潘庚.改良康复新液保留灌肠治疗溃疡性结肠炎的疗效及对复发率的影响[J].中国老年学杂志,2012,32(11):2401-2402.
[16]	Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembollism[J]. Cut,2004,53(4):542-548.
[17]	陆春霞,梅俏,章礼久,等.活动期溃疡性结肠炎中血小板计数的变化及临床意义[J].安徽医药,2011,15(12):1536-1537.
[18]	刘英超.溃疡性结肠炎患者凝血指标的临床意义[J].浙江医学,2008,30(8):871-872.
[19]	谭悦,杨俊,郑长青,等.美沙拉嗪口服联合灌肠治疗溃疡性结肠炎的疗效评价[J].实用药物与临床,2012,15(6):344-346.